[Sarcoidosis following pegylated interferon therapy: two cases].
One side effect of the immunomodulatory effect of interferon is the possible triggering or exacerbation of systemic or cutaneous sarcoidosis. We report two new cases and offer an exhaustive review of the literature. A 39-year-old man with type C chronic active hepatitis developed new respiratory symptoms and pulmonary infiltrates with hilar and mediastinal adenopathy after 7 months of treatment with pegylated interferon. The evolution was favourable after stopping treatment. The second patient developed cutaneous lesions after 6 months of treatment. Resolution occurred after the discontinuation of the treatment. In these two cases ribavirin was stopped before the first signs of sarcoidosis.
Benali
Souad
S
Service d'Hépato-Gastroentérologie, Hôpital Saint Joseph, Marseille.
Boustière
Christian
C
Castellani
Paul
P
Cesari
Christine
C
Jullien
Monique
M
Lecomte
Laurence
L
Lebars
Olivier
O
Lambot
Gérard
G
Loyer
Robert
R
Masseboeuf
Amina
A
Perrier
Hervé
H
Oules
Valérie
V
Bourlière
Marc
M
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a